{"nctId":"NCT00090753","briefTitle":"A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia","startDateStruct":{"date":"2004-10"},"conditions":["Anemia"],"count":1228,"armGroups":[{"label":"Methoxy Polyethylene Glycol-Epoetin Beta","type":"EXPERIMENTAL","interventionNames":["Drug: Methoxy Polyethylene Glycol-Epoetin Beta"]},{"label":"Comparator ESA","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Epoetin alfa","Drug: Epoetin beta","Drug: Darbepoetin alfa"]}],"interventions":[{"name":"Methoxy Polyethylene Glycol-Epoetin Beta","otherNames":["RO0503821","Mircera"]},{"name":"Epoetin alfa","otherNames":[]},{"name":"Epoetin beta","otherNames":[]},{"name":"Darbepoetin alfa","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent\n* Adult patients (≥ 18 years old) with chronic renal anemia\n* Maintenance erythropoietic therapy with methoxy polyethylene glycol-epoetin beta or a protocol-specified reference medication (epoetin alfa formulated with human albumin, epoetin beta or darbepoetin alfa) in one of the following studies: BA16528\\[NCT00048048\\], BA16285\\[NCT00048035\\], BA16286\\[NCT00364832\\], BA16736\\[NCT00077597\\], BA16738\\[NCT00081471\\], BA16739\\[NCT00077610\\], BA16740\\[NCT00077623\\], BA17283\\[NCT00077766\\] and BA17284\\[NCT00081484\\]\n* Hemoglobin (Hb) concentration between 10.5 and 13.0 g/dL\n* Adequate iron status defined as serum ferritin ≥ 100 ng/mL or Transferrin Saturation (TSAT)≥ 20% or percentage of hypochromic red blood cells (RBCs) \\< 10%\n\nExclusion Criteria:\n\n* Poorly controlled hypertension\n* History of epileptic seizure\n* Pure red cell aplasia\n* Chronic congestive heart failure \\[New York Heart Association (NYHA) IV\\]\n* High likelihood of early withdrawal or interruption of the study\n* Active malignant disease (except non-melanoma skin cancer)\n* Life expectancy less than 12 months\n* Pregnancy or breast-feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin Concentration to the Last Month of Study Participation","description":"Blood samples were collected at each study visit, that is, every 4 weeks for the first 12 weeks, every 12 weeks until week 105 of the first study period, every 3 months thereafter, and at the end of study or the last visit if the patient discontinued the study prematurely.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.55","spread":"1.832"},{"groupId":"OG001","value":"-0.38","spread":"1.614"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Had at Least 1 Adverse Event","description":"See the adverse events section of the results for more information.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.3","spread":null},{"groupId":"OG001","value":"93.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":499,"n":748},"commonTop":["HYPERTENSION","DIARRHOEA","NASOPHARYNGITIS","PROCEDURAL HYPOTENSION","UPPER RESPIRATORY TRACT INFECTION"]}}}